Hopstem is dedicated to developing innovative off-shelf allogeneic iPSC cell therapy products for global CNS and other challenging diseases patients. Since 2017, Hopstem has established cutting-edge iPSC platform of cellular reprogramming, genetic engineering, neural differentiation, manufacturing processes and analytic methods with PCT patents and quality system. Hopstem has raised more than 70 million USD fund from VCs, about 100 employees and 90,000 sqft R&D and GMP manufacturing sites. The first allogenic cell therapy product hNPC01, a forebrain neural progenitor cell injection derived from iPSC, is under phase I clinical trial targeting chronic ischemic stroke in China, with recent IND approval from FDA. Other pipelines of same and different cell products target indications such as traumatic brain injury, epilepsy, etc. Hopstem believes that innovative cell engineering technology will bring more stable, safe, effective and affordable cell products to improve the quality of life.